TSXV:CLAS.H - Post by User
Comment by
WORKINMONTANAon Jun 05, 2019 5:13pm
![](https://assets.stockhouse.com/kentico-cms/0341-00/images/Sprite.svg#id_Post_Views_Icon)
102 Views
Post# 29800996
RE:updates shortly, as per KLY ceo
RE:updates shortly, as per KLY ceo News releases from March 20, 2018 Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the Company or Kalytera) today announced that it is has begun development of a novel cannabinoid-based compound for the treatment of acute and chronic pain. Patents for this compound have been filed in the U.S. and other jurisdictions, and Kalytera has obtained an exclusive, worldwide license for this compound from Beetlebung Pharma, Ltd., an Israeli-based pharmaceutical discovery company focused on cannabinoid-based therapeutics for the treatment of human disease (BPL). 16 Months later investors get this update... GLTA
junior6grinder wrote: "We have also made good progress in our program to develop the first cannabinoid-derived pain treatment targeting activation of alpha3 glycine pain receptors, and we will provide additional updates on both of these programs shortly". (stated May 31st, Q1 financials) glta